29 Jan 2020
Discover unmet pharmaceutical needs. Effectively prioritize market opportunities. Deliver optimal returns. Datamonitor Healthcare’s in-depth expert data analysis and robust interactive data tools meet your needs and address your challenges in an ever-changing market.
How it helps
The breadth of coverage ensures you can assess revenue potential and identify competitive threats, market catalysts, and untapped new product development opportunities more holistically than ever before.
How it works
Content created by a global team of award-winning specialist analysts, and an easy-to-use interface that streamlines information gathering make Datamonitor Healthcare the go-to solution for the pharmaceutical and biotechnology industries.
Gauge the relative strength of upcoming drugs with our drug comparator tool. Identify untapped opportunities with our state-of-the art, interactive forecasting tool, event-driven forecasts updated within 48 hours, and patient-based sales forecasts from surveys of more than 200 physicians per indication.
Receive accurate replies to your queries in minutes, not hours with 24/7 live customer support. Stay up-to-speed on the latest market developments with customizable email alerts that notify you of updates to the information most important to you.
By Niharika Dandamudi 28 Jan 2020
Cardiovascular Diseases (CVDs) are one of the leading causes of disease burden worldwide. This epidemiology overview presents the prevalence of some CVDs and their associated clinical risk factors analyzed by Datamonitor Healthcare.
By Joseph Haas 04 Nov 2019
Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.
Awareness, Datamonitor Healthcare
31 Oct 2019
Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.
Biomedtracker, Datamonitor Healthcare
31 Oct 2019
Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.
10 Oct 2019
The Commercial Solutions Strategy Suite from Informa Pharma Intelligence unites the power of vital tools to bring you actionable data, penetrating analysis, and a crucial industry view covering a variety of critical market aspects, allowing you to accurately Forecast, Analyze and Benchmark, and Understand the mark landscape.
Biomedtracker, Datamonitor Healthcare
27 Sep 2019
Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.
By Amanda Micklus 27 Sep 2019
As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.
Topic Cell and gene therapy
03 Sep 2019
As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations
Topic Drug review
16 Aug 2019
Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.
15 Jul 2019
Our latest whitepaper lists the top selling drugs last year, who developed them and the strategies behind their success. We drew from three of our top products to create our most recent whitepaper, Datamonitor Health Care, Biomedtracker and Pharmaprojects. You can experience them all for yourself.
Datamonitor Healthcare, Biomedtracker, Pharmapremia
By Hardik Patel 15 Jul 2019
Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019.
03 Jul 2019
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: